
Helen L Pilmore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7693386/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, S11-S103.	1.0	306
2	Reduction in Cardiovascular Death After Kidney Transplantation. Transplantation, 2010, 89, 851-857.	1.0	181
3	Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 318-326.	11.4	93
4	Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. Journal of the American Society of Nephrology: JASN, 2020, 31, 2887-2899.	6.1	92
5	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, 708-714.	1.0	73
6	<scp>KHAâ€CARI G</scp> uideline: <scp>R</scp> ecipient <scp>A</scp> ssessment for <scp>T</scp> ransplantation. Nephrology, 2013, 18, 455-462.	1.6	63
7	Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology, 2010, 15, 412-418.	1.6	62
8	Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes and Endocrinology,the, 2017, 5, 26-33.	11.4	57
9	Cardiovascular Disease Medications After Renal Transplantation: Results From the Patient Outcomes in Renal Transplantation Study. Transplantation, 2011, 91, 542-551.	1.0	45
10	The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney International, 2017, 91, 954-963.	5.2	44
11	Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease—A trial protocol for the CARSK study. American Heart Journal, 2019, 214, 175-183.	2.7	43
12	Hepatitis B–Positive Donors in Renal Transplantation. Transplantation, 2012, 94, 205-210.	1.0	39
13	A randomized, controlled trial of everolimusâ€based dual immunosuppression versus standard of care in <i>de novo</i> kidney transplant recipients. Transplant International, 2014, 27, 302-311.	1.6	39
14	Longâ€ŧerm outcomes for primary glomerulonephritis: <scp>N</scp> ew <scp>Z</scp> ealand <scp>G</scp> lomerulonephritis <scp>S</scp> tudy. Nephrology, 2015, 20, 899-907.	1.6	31
15	Changes in high sensitivity troponin T in incident haemodialysis patients. New Zealand Medical Journal, 2016, 129, 23-34.	0.5	31
16	Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clinical Transplantation, 2002, 16, 191-195.	1.6	30
17	Fatal Human Herpesvirus-6 Infection After Renal Transplantation. Transplantation, 2009, 88, 762-765.	1.0	24
18	Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in im impaired glucose tolerance after kidney transplantation. BMC Nephrology, 2019, 20, 147.	1.8	23

Helen L Pilmore

#	Article	IF	CITATIONS
19	Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. CKJ: Clinical Kidney Journal, 2013, 6, 402-409.	2.9	20
20	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.	2.8	20
21	De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. American Journal of Transplantation, 2018, 18, 2977-2986.	4.7	15
22	Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. BMJ Open, 2017, 7, e016813.	1.9	14
23	Cardiovascular disease in patients with chronic kidney disease. Nephrology, 2014, 19, 3-10.	1.6	12
24	Impact of chronic kidney disease on mortality and cardiovascular outcomes after acute coronary syndrome: A nationwide data linkage study (ANZACSâ€QI 44). Nephrology, 2020, 25, 535-543.	1.6	11
25	Management of coronary artery disease in patients on dialysis. New Zealand Medical Journal, 2017, 130, 11-22.	O.5	11
26	Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause. Scientific Reports, 2018, 8, 9021.	3.3	10
27	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney and Blood Pressure Research, 2017, 42, 1033-1044.	2.0	7
28	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 0, , .	2.8	5
29	Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?. Transplant Infectious Disease, 2017, 19, e12631.	1.7	5
30	Communicating projected survival with treatments for chronic kidney disease: patient comprehension and perspectives on visual aids. BMC Medical Informatics and Decision Making, 2017, 17, 137.	3.0	5
31	KHA ARI guideline: Cytomegalovirus disease and kidney transplantation. Nephrology, 2011, 16, 683-687.	1.6	4
32	Donor Characteristics of Pancreas Transplantation in Australia and New Zealand: A Cohort Study 1984-2014. Transplantation Direct, 2016, 2, e99.	1.6	4
33	Australia and New Zealand Islets and Pancreas Transplant Registry Annual Report 2018—Pancreas Waiting List, Recipients, and Donors. Transplantation Direct, 2018, 4, e390.	1.6	4
34	Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. Transplantation, 2019, 103, 1705-1713.	1.0	4
35	Australia and New Zealand Islet and Pancreas Transplant Registry Annual Report 2019—Pancreas Waiting List, Recipients, and Donors. Transplantation Direct, 2020, 6, e564.	1.6	3
36	Interactions Between Donor Age and 12-Month Estimated Glomerular Filtration Rate on Allograft and Patient Outcomes After Kidney Transplantation. Transplant International, 2022, 36, 10199.	1.6	3

Helen L Pilmore

#	Article	IF	CITATIONS
37	Prognostic value and long-term variation of high sensitivity troponin T in clinically stable haemodialysis patients. New Zealand Medical Journal, 2014, 127, 97-109.	0.5	3
38	Deceased donor kidney transplantation in New Zealand: use and audit of a survival prediction tool. New Zealand Medical Journal, 2017, 130, 33-39.	0.5	3
39	End-stage renal failure in New Zealand Maori: An analysis of circulating transforming growth factor-beta1. Nephrology, 2002, 7, 18-22.	1.6	2
40	Cardiac Screening for Kidney Transplantation. Transplantation, 2016, 100, 1396-1397.	1.0	2
41	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	1.6	2
42	Early Graft Loss Following Transplantation From Expanded Criteria Donors. Transplantation Direct, 2021, 7, e783.	1.6	2
43	Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes. Nephrology, 2007, 12, S88-S97.	1.6	1
44	Review article: Coronary artery stenoses: Detection and revascularization in renal disease. Nephrology, 2009, 14, 537-543.	1.6	1
45	Re: "Cardiac Assessment for Renal Transplant". American Journal of Transplantation, 2006, 6, 1979-1979.	4.7	0
46	Association of prevalent vascular disease with allograft failure and mortality in liveâ€donor kidney transplant recipients – a retrospective cohort study. Transplant International, 2019, 32, 1161-1172.	1.6	0
47	Increased Peripheral Blood Heteroplasmy of the mt.3243A>G Mutation Is Associated with Earlier End-Stage Kidney Disease: A Case Report and Review of the Literature. Nephron, 2020, 144, 358-362.	1.8	0